홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
FHTX
#2701
Foghorn Therapeutics Inc. Common Stock
5.680
0
+0.89%
부문:
베이스:
수익 통화:
일일 변동 비율
년간 변동
일일 변동
+0.89%
월간 변동
-3.97%
6달 변화
+39.22%
년간 변동율
+39.22%
이전 종가
5.630
0
Open
5.680
0
Bid
Ask
Low
5.680
0
High
5.680
0
양
33
마켓
주식
헬스케어
FHTX
Open full chart
Financials
Overview
성명
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
36.82 M
41.42 M
41.8 M
42.57 M
55.61 M
—
Valuation ratios
Enterprise value
653.48 M
846.18 M
219.51 M
194.21 M
207.04 M
729.79 M
Price to earnings ratio
—
-8.38
-2.48
-2.76
-2.99
-14.63
Price to sales ratio
—
644.51
14.06
7.93
11.46
44.83
Price to cash flow ratio
—
16.92
1.4
2.29
2.58
11.27
Price to book ratio
—
8.78
2 413.79
3.51
5.69
9.58
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.27
0.19
0.27
0.34
0.3
0.3
Return on equity %
0.47
1.05
972.32
1.27
1.9
1.14
Return on invested capital %
182.8
188.74
159.43
156.66
202.12
—
Gross margin %
100
100
100
100
100
400
Operating margin %
15.94 K
7 637.15
609.2
315.93
454.31
1 731.57
EBITDA margin %
—
—
—
—
—
—
Net margin %
16 K
7 680.06
566.36
288.1
383.15
1 429.78
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
10.12
9.44
6.37
4.11
3.73
11.67
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0
0.04
0.1
0.08
0.1
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
0.08
0
—
—
—
—
Long term debt to total equity ratio
0.13
0
—
—
—
—
Per share metrics
Operating cash flow per share
—
1.35
4.66
2.81
1.83
1.46
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
2.72
1.26
1.91
1.01
4.55
Net current asset value per share
—
12.36
8.45
5.72
4.55
14.29
Tangible book value per share
—
2.61
0
1.84
0.83
4.45
Working capital per share
—
11.05
7.12
4.33
3.33
9.35
Book value per share
—
2.61
0
1.84
0.83
4.45
뉴스
Foghorn Therapeutics names Ryan Maynard as chief financial officer
제퍼리스, 포그혼 테라퓨틱스에 매수 등급 제시
Jefferies initiates Foghorn Therapeutics stock with buy rating
BTIG 선정, 2026년 최고 헬스케어 주식
Top Healthcare Stocks for This Year According to BTIG
포그혼 테라퓨틱스, BTIG ’매수’ 등급 재확인...2026년 상반기 최선호주로 선정
Foghorn Therapeutics stock reaffirmed as Buy by BTIG, named top pick for 1H26
스티펠, Foghorn Therapeutics에 ’매수’ 등급 재확인, 목표가 12달러
Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 target
3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment
포그혼 테라퓨틱스, BTIG ’매수’ 등급 개시, 암 파이프라인 주목
BTIG initiates Foghorn Therapeutics stock with Buy rating on cancer pipeline